IP Library Granted Patent US 10,738,133
Granted Patent B2
US 10,738,133 · App. 15/589,908 · Granted Aug 11, 2020

Heterodimeric proteins

Inventors: Gregory Moore (Arcadia, CA); Matthew Bernett (Monrovia, CA); Rumana Rashid (Arcadia, CA); John Desjarlais (Pasadena, CA)
Assignee: Xencor, Inc.
C07K16/468C07K16/2803C07K16/2809C07K16/2896C07K2317/31C07K2317/51C07K2317/515C07K2317/52C07K2317/528C07K2317/55C07K2317/565C07K2317/622C07K2317/64C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,133
App. No.
15/589,908
Granted
Aug 11, 2020
Kind
B2
Abstract

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Claims (16)

1. A heterodimeric antibody comprising:

a) a first monomer comprising an anti-CD3 scFv-hinge-CH2-CH3 monomer, wherein CH2-CH3 is a first variant Fc domain and said anti-CD3 scFv comprises an scFv variable heavy chain comprising SEQ ID NO: 397, an scFv variable light chain comprising SEQ ID NO: 398 and a charged linker comprising SEQ ID NO: 450;

b) a second monomer comprising a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a first variable heavy chain and CH2-CH3 is a second variant Fc domain; and

c) a light chain comprising a first variable light chain;

wherein said CH1-hinge-CH2-CH3 of said second monomer comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D,

wherein said first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, and

wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein numbering is according to the EU index as in Kabat.

2. The heterodimeric antibody of claim 1 , wherein said first and second variant Fc domains are variant human IgG1, IgG2 or IgG4 variant Fc domains.

3. The heterodimeric antibody of claim 1 , wherein said first and second variant Fc domains are variant human IgG1 Fc domains.

4. A nucleic acid composition comprising:

a) a first nucleic acid encoding said first monomer of claim 1 ;

b) a second nucleic acid encoding said second monomer of claim 1 ; and

c) a third nucleic acid encoding said light chain of claim 1 .

5. An expression vector comprising said first nucleic acid, said second nucleic acid and said third nucleic acid of claim 4 .

6. A host cell comprising said expression vector of claim 5 .

7. A method of producing the heterodimeric antibody of any one of claims 1 to 3 comprising culturing the host cell of claim 6 under conditions to produce the heterodimeric antibody and recovering the heterodimeric antibody from the cell culture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2019
From: MOORE, GREGORY; RASHID, RUMANA; DESJARLAIS, JOHN; BERNETT, MATTHEW
To: XENCOR, INC.
Reel/Frame 049947/0607 →
Continuity (11)
Continuation 14205248 · Mar 11, 2014
Continuation 14155334 · Jan 14, 2014
Provisional Application 61913832 · Dec 9, 2013
Provisional Application 61913870 · Dec 9, 2013
Provisional Application 61818410 · May 1, 2013
Provisional Application 61818153 · May 1, 2013
Provisional Application 61780334 · Mar 13, 2013
Provisional Application 61778157 · Mar 12, 2013
Provisional Application 61764954 · Feb 14, 2013
Provisional Application 61752348 · Jan 14, 2013
Related Publication 20180142040A1 · May 24, 2018
Cited By (9)
US 12,359,002 US 12,398,207 US 12,404,329 US 12,415,849 US 12,466,897 US 12,617,872 US 12,655,230 US 12,662,553 US 12,698,341